B. Riley Research Analysts Lift Earnings Estimates for OBIO

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Stock analysts at B. Riley upped their FY2024 EPS estimates for shares of Orchestra BioMed in a research note issued on Wednesday, November 13th. B. Riley analyst K. Bauser now expects that the company will earn ($1.67) per share for the year, up from their previous forecast of ($1.70). B. Riley has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.67) per share. B. Riley also issued estimates for Orchestra BioMed’s Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.57) EPS and FY2025 earnings at ($2.08) EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Orchestra BioMed in a research note on Friday. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Wednesday, November 13th.

Orchestra BioMed Stock Performance

Shares of OBIO opened at $5.83 on Monday. The business’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $6.27. The firm has a market capitalization of $221.60 million, a price-to-earnings ratio of -3.62 and a beta of 0.42. Orchestra BioMed has a 52 week low of $4.22 and a 52 week high of $11.69.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.03. Orchestra BioMed had a negative net margin of 2,179.33% and a negative return on equity of 107.04%. The business had revenue of $0.99 million for the quarter, compared to analysts’ expectations of $0.81 million.

Insider Activity

In related news, insider Darren Sherman sold 6,804 shares of Orchestra BioMed stock in a transaction on Monday, September 9th. The stock was sold at an average price of $5.48, for a total transaction of $37,285.92. Following the completion of the sale, the insider now directly owns 772,691 shares of the company’s stock, valued at $4,234,346.68. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 24,260 shares of company stock valued at $138,573 in the last 90 days. 6.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Orchestra BioMed

Several hedge funds have recently added to or reduced their stakes in OBIO. SG Americas Securities LLC acquired a new position in shares of Orchestra BioMed during the 3rd quarter worth about $52,000. ABLE Financial Group LLC bought a new position in Orchestra BioMed during the 3rd quarter worth approximately $69,000. Catalytic Wealth RIA LLC acquired a new position in Orchestra BioMed during the first quarter valued at approximately $117,000. Barclays PLC increased its stake in Orchestra BioMed by 281.3% in the third quarter. Barclays PLC now owns 31,785 shares of the company’s stock valued at $163,000 after purchasing an additional 23,448 shares in the last quarter. Finally, SkyView Investment Advisors LLC acquired a new stake in Orchestra BioMed in the second quarter worth $163,000. Institutional investors and hedge funds own 53.55% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.